I N OTHERWISE HEALTHY CHILDREN. ACUTE BONE AND JOINT
infections can be managed effectively using a sequential intravenous-oral antibiotic regimen (l-12) . This approach offers several advantages over the traditional alternative of three to six weeks of in-hospital intravenous therapy, including: decreased risk of complications associated with intravenous lines; greater comfort and ease of therapy for the patient; decreased cost; and, for the child who is able to complete oral therapy at home, a shorter stay in hospital. Therapeutic failure with development of chronic infection is a theoretical but rare occurrence that should be avoidable provided patients are carefully selected and monitored. The Canadian Paediatric Society has reviewed the available data in order to outline the clinical situations in which a sequential intravenous-oral antibiotic regimen should be considered as well as to emphasize the important principles of management that must be employed if such therapy is to be successful.
WHEN SHOULD SEQUENTIAL INTRAVENOUS-ORAL ANTIBIOTIC THERAPY BE CONSIDERED?
The fo llowing conditions are most conducive to successful outcome of oral therapy:
• 
WHEN CAN ORAL THERAPY BE STARTED?
Once there is evidence of definite clinical improvement in both systemic and local signs of inflammation and the child is eating normally, oral therapy can be considered. This status usually occurs within several days of hospitalization, although convalescence may be slower in children with more extensive disease or in whom surgical intervention was necessary. Special consideration is required for children one year of age of younger, since they have the highest incidence of complications following bone and joint infections, especially those involving the hip. A decline in erythrocyte sedimentation rate (ESR) may lag behind other evidence of disease resolution, and thus is not a reliable guide for deciding when to start oral therapy (1, 13, 14) .
WHAT ANTIBIOTICS ARE APPROPRIATE FOR USE IN ORAL THERAPY?
The dosage of oral antibiotic is two-to threefold higher than what would normally be used for treating less serious out-patient infections. Surprisingly, gastrointestinal intolerance with such high doses is uncommon (1).
The majority of bone and joint infections in children are caused by S aureus or H influenzae. The choices and dosage regimens for oral antibiotics to treat these isolates are indicated in 
WHAT ARE THE INDICATORS OF SUCCESSFUL TREATMENT?
Clinical and laboratory evidence of resolution of infection and associated inflammation should be meticulously documented in all children with bone and joint infections irrespective of the route of therapy. There should be resolution of fever, p r ogressive decrease in local signs of inflammation and resumption of normal skeletal function. Although ESR often increases during the first week of hospitalization, subsequent gradual retum to normal is an excellent pr edictor of successful outcome and may be used to determine the end-point of therapy.
HOW SHOULD ORAL THERAPY BE MONITORED?
The key strategy for monitoring oral antibiotic therapy of bone and joint infections is demonstration that drug absorption is adequate to achieve therapeutic serum concentrations. Despite the high doses used, up to 10% of children receiving oral penicillins and cephalosporins will have less than adequate absorption (1). Thus , oral_ therapy should not be undertaken unless the serum level of antibiotic can be monitored in some way.
A relatively simple way to assess the adequacy of antibiotic absorption is to determine the serum bacte-
riocidal titre (SBT) for orally administered penicillins and cephalosporin, or the serum inhibitory titre (SIT) for oral clindamycin. For both the SIT and SBT, the original bacterial isolate is added to serial d ilutions of the patient's serum sampled at a time of expected peak antibiotic concentration (45 to 90 mins after an oral dose). The initiation of oral therapy needs to be coord inated with t11e labor atory so that an SIT/SBT can be done approximately 24 h after starting oral therapy. The test takes 24 h (SIT) to 48 h (SBT) to complete. If there is concem about inadequate drug absorption , intravenous therapy can be resumed while awaiting results. The laboratory records the h ighest dilution of serum in which 99.9% or more of the patient's miginal bacterial inoculum has been inhibited (SIT) or killed (SBT). The desired peak titre is ~1: 8 Failure to achieve this level may be due to: an insufficient dose of antibiotic (due to medication error, lack of compliance, or emesis); inappropriate timing of obtaining the post-dose b lood sample; delay in getting the sample to the laboratory: or laboratory error. If any of these occurs. the test should be repeated. Altemately. gastrointestinal absorption of antib iotic may have been inadequate, in which case consideration must be given to an altemate oral antibiotic regimen or retuming to treatment with intravenous antibiotics. In general, the SIT/SBT should be repeated each time there is a change in the type or dose of antibiotic.
WHEN IS OUT-PATIENT TREATMENT WITH ORAL THERAPY APPROPRIATE?
Compliance is the key factor to be considered in deciding whether a child should be allowed to complete the therapeutic course at home. Unless a physician is total ly confident that the child's guardians will ensure that all doses of the drug are given as prescribed. completion of oral therapy shou ld be carried out in hospital. If it is decided that the child can be discharged home, it is essential that there be weekly supervision for the remainder of the treatment course, in order to ll monitor the child's clinical status and compliance with medication . This can be done through a combination of clinic visits and telephone contacts . If there are dou bts about compliance, a repeat SIT/SBT should be done.
HOW LONG SHOULD THERAPY BE CONTINUED?
Whether therapy is given entirely by intraveno u s or sequential intravenous-oral routes, the minimal d u ration of therapy is: for septic arthritis, two weeks if caused by H injluenzae and three weeks if caused by S aureus, S pneumoniae, or group A beta hemolytic streptococcus; for osteomyelitis, four weeks. Therapy should be extended if there is still clinical or laboratory evidence of inflammation.
CONCLUSION
This summary is not meant to be an exhaustive review. The outcome of treatment of skeletal infection is a function of numerous variables, including the characteristics of both the pathogen and the host, the site of involvement, the duration of disease before treatment, the adequacy of surgical intervention and the provision of effective antibiotic therapy. When possible, multidisciplinary management of children with bone and/or joint infection is optimal and should include individuals with expertise in pediatrics for overall patient care and coordination of subspecialty input; orthopedic surgeons for advice and assistance about the use of surgical intervention for etiological diagnosis and management; and infectious disease specialists for advice, and assistance about appropriate specimen collection and handling for bacterial culture, as well as subsequent initiation and monitoring of oral antibiotic therapy.
